METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion
Stem Cells Translational Medicine · 23.03.2026 · 15 (4)
DOI: 10.1093/stcltm/szag016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 29.03.2026. Verfasst von Jiang Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Henan Collaborative Innovation Center of Stem Cells and Biotherapy, School of Medical Engineering, Henan Medical University (Xinxiang Medical Univers…. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Methyltransferases, Nicotinamide Phosphoribosyltransferase, Cytokines. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Henan Province.
Abstract (Originalsprache)
Background
Genetically modified mesenchymal stem cells (MSCs) have been shown to enhance their therapeutic properties, offering more effective treatment options for various diseases, including metabolic associated fatty liver disease (MASLD). The m7G methyltransferase METTL1 plays a critical role in regulating RNA splicing, stability, and translation. This study presents our findings on METTL1 modified human umbilical cord MSCs, emphasizing their therapeutic effects and the mechanisms involved in treating MASLD.
Methods
METTL1 knockdown MSCs were generated via lentiviral shRNA. Key characteristics, including senescence, proliferation, cell cycle, and apoptosis, were assessed in vitro. A high-fat diet (HFD)-induced MASLD mouse model was used to evaluate the effects of MSC transplantation through serological, biochemical, and pathological analyses. Molecular mechanisms were explored using immunofluorescence (IF), Western blotting (WB), and quantitative PCR (qPCR).
Results
Our results indicate that METTL1-deficient MSCs exhibit reduced proliferative capacity and increased susceptibility to senescence and apoptosis. Remarkably, these MSCs significantly decreased lipid accumulation in both in vitro and in vivo MASLD models. We found that METTL1-deficient MSCs secrete higher levels of NAMPT, which activates SIRT1, leading to the inhibition of SREBP1-mediated lipogenic genes. Inhibition of NAMPT reversed the protective effects of METTL1-deficient MSCs against MASLD-related lipid metabolic disorders. Furthermore, overexpression of METTL1 in MSCs exacerbated lipid metabolic disorders in MASLD mice by inhibiting the NAMPT/SIRT1/SREBP1 signaling pathway.
Conclusion
METTL1-deficient MSCs alleviate MASLD-associated lipid metabolic disorders via NAMPT secretion. This suggests that genetically modified MSCs targeting METTL1 may represent a promising therapeutic strategy for the treatment of MASLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Henan Collaborative Innovation Center of Stem Cells and Biotherapy, School of Medical Engineering, Henan Medical University (Xinxiang Medical University), Xinxiang 453003, China.
- Henan Joint International Research Laboratory of Stem Cell Medicine, School of Medical Engineering, Henan Medical University (Xinxiang Medical University), Xinxiang 453003, China.
- School of pediatrics, Henan Medical University (Xinxiang Medical University), Xinxiang 453003, China.
- Department of Gastroenterology, Institute of Digestive Diseases of PLA, The First Affiliated Hospital (Southwest Hospital) of Third Military Medical University (Army Medical University), Chongqing 400038, China.
ORCID-Profile: Juntang Lin
Förderung
- Natural Science Foundation of Henan Province
Zitieren
APA
Du, J., Zhang, Y., Wang, C., Wang, Y., Zhang, H., Zhao, D., & Lin, J. (2026). METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion. Stem Cells Translational Medicine, 15(4). https://doi.org/10.1093/stcltm/szag016
Vancouver
Du J, Zhang Y, Wang C, Wang Y, Zhang H, Zhao D, et al. METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion. Stem Cells Translational Medicine. 2026;15(4). doi:10.1093/stcltm/szag016
BibTeX
@article{Du2026,
author = {Du, Jiang and Zhang, Yuxuan and Wang, Chiheng and Wang, Yuyuan and Zhang, Hongen and Zhao, Dunyong and Lin, Juntang},
title = {METTL1-deficient mesenchymal stem cells protect against metabolic-associated fatty liver disease by increasing NAMPT secretion},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {4},
doi = {10.1093/stcltm/szag016}
}
EUVIMED